Infectious Diseases
Predictive solutions combine proprietary surveillance tools and forecast models with expert analysis to produce actionable insights across pipeline developments, standard of care, regulatory trends, market analysis and supply and demand.
Data-driven Solutions for Improved Health Outcomes
Disease-centric solutions combine proprietary surveillance tools and forecast models with expert analysis to produce actionable insights across pipeline developments, standard of care, regulatory trends, market analysis and supply and demand.
By linking data points and building up historical correlation models, we can provide near real time data driven assessments of the impact of a new development. Bottom-up forecasts are built by subject matter experts who analyse, commentate and contextualise all our data through platform insights, searchable reports and regular in-person briefings.
Platforms
All data and information in one place, accessible 24/7 with daily updates on everything infectious disease.
Intelligence Reports
Providing insight and context around key movements across the infectious diseases space.
Disease Outcomes Services
Tailored service providing independent forecasts and intelligence on population-level impacta of a disease.
Airfinity’s Forecasting and Intelligence Service
A fully bespoke service that builds and deploys cutting-edge modelling capabilities to suit your organisation’s needs for infectious disease forecasting and intelligence-gathering.
Disease Burden
Build evidence packages that can be used to seek label expansion, make a stronger and more data-driven health economic case, and quantify the size of an opportunity.
Forecasting and Simulations
Predict demand by volume and price for a given candidate or drug-class, informing market access, manufacturing and commercial strategies.
Drivers of Patient Outcomes
Identify how much a candidate might reduce the burden of disease and simulate outcomes based on different utilisation scenarios.
Analysis & Insights
Elderly RSV vaccines to generate $10.5B annually by 2030 in G7 countries
Airfinity releases new forecasts on the market for elderly RSV vaccines in the G7, expecting it to make $900m this year.
Read More →
More from Airfinity
A strong pandemic defence system could reduce the chance of another COVID like pandemic in the next ten years from 27.5% to 8%
Elderly RSV vaccines to generate $10.5B annually by 2030 in G7 countries
The Post-Pandemic Tripledemic: Forecasting the burden of Influenza, RSV, and COVID-19
Airfinity launches intelligence tool to drive innovation in AMR research
China’s second COVID-19 wave to be smaller than its first peaking at 11 million cases a week, predicts Airfinity
View All →
Product Platforms
All-in-one data resource for exploration across historical and current infectious disease intelligence, updated in real-time with extensive filters and search functionality.
Infectious Disease Analytics (IDA)
New science and competitive intelligence for all indications across the infectious disease landscape.
Learn more →
Biorisk
Monitor all pathogenic threats in real time, with real-time alerts and analysis on emerging outbreaks and infectious disease risks.
Learn more →
Respiratory Diseases
New science and commercial intelligence for all COVID-19, RSV, and Influenza candidates, including detailed epidemiology analysis.
Learn more →
RNA
Extensive pipeline surveillance and intelligence for the RNA landscape, tracking delivery mechanisms, and providing a holistic overview of market dynamics.
Learn more →
Intelligence Reports
Deep dives and syndicated analysis that is of interest and importance to your business needs.
By Disease
Comprehensive overview of the current state of play for a specific disease, including epidemiological trends, pipeline overview and predictions, and market intelligence and demand forecasting.
By Country
Dig deeper into the epidemiological trends for a disease in your country of choice, and analysing multiple data sources levels to provide actionable insights and short-term predictions.
By Topic
From AAV Gene Therapy to Antimicrobial Resistance, Airfinity provides detailed overviews of a particular technology or topic, as well as the implications for the wider infectious disease landscape.
Case Study
COVID-19 Vaccines: Lives Saved Analysis
A leading pharmaceutical producer wanted to understand how many lives their COVID-19 vaccine saved. This analysis was required to determine the value of the different vaccines in relation to how much the burden of disease was reduced using each of these candidates.
Our Approach
A mathematical modelling study published in Lancet Infectious Diseases that estimated the total number of lives saved in the first year of COVID-19 vaccinations. Thanks to Airfinity’s unique historical datasets and models, we were able to break this number down by individual vaccine, identifying the distribution in reduction of the burden of disease.
The Outcome
According to our model, AstraZeneca’s COVID-19 vaccine Vaxzevria saved 6.3 million lives and Pfizer/BioNTech’s Comirnaty saved 5.9 million lives. This was picked up globally by mainstream media with a reach of over 270 million, and used in the UK Budget 2023, AstraZeneca’s quarterly earnings report, as well as in other vaccine producers’ external communications.